On April 3, 2026, Hagens Berman, a prominent national law firm specializing in shareholder rights, announced an ongoing investigation into uniQure N.V. (NASDAQ: QURE) following a string of notable criticisms by Food and Drug Administration (FDA) officials. The investigation was launched subsequent to the submission of a filing.